Tagrisso (osimertinib)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card
Enquire now
We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Tagrisso (osimertinib)

How to buy Tagrisso: You can order Tagrisso (osimertinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer AstraZeneca
Disease Lung Cancer
Indication Advanced or metastatic NSCLC with T790M mutation
Mode of Action Kinase inhibitor (targeted therapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
CAS Number 1421373-65-0
HS Code 30049000
Strength 40 mg, 80 mg

Who is osimertinib for?

Tagrisso (osimertinib) is indicated for the treatment of advanced or metastatic NSCLC in patients with epidermal growth factor receptor (EGFR) T790M mutation [1][2][3].

Recommended dose

Complete information about Tagrisso (osimertinib) dosage and administration can be found here [1][2][3].
The standard dosage is:
  • 80 mg orally once daily
Consult your treating doctor for personalised dosing.

What is osimertinib and how does it work?

Tagrisso (osimertinib) is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC) [1][2][3].

It blocks the activity of EGFR, which normally controls growth and division of cells. In lung cancer cells, EGFR is often overactive, causing uncontrolled division of cancer cells. By blocking EGFR, osimertinib helps to reduce the growth and spread of the cancer. Unlike most other tyrosine kinase inhibitors, Tagrisso (osimertinib) is active against cancer cells with the T790M mutation in the EGFR gene [4].

What is osimertinib's approval status?

Tagrisso (osimertinib) was approved by:
  • FDA (USA) on November 13, 2015 [5]with accelerated approval and on March 30, 2017 [6] with regular approval
  • EMA (EU) on February 2, 2016 [4]
  • TGA (AUS) on August 3, 2016 [3]
for the treatment of metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC). 

The approvals of osimertinib for T790M mutation positive NSCLC were based on two single-arm, open-label clinical studies, AURAex (Phase II Extension cohort, (n=201)) and AURA2 (n=210) involving patients who had progressed on one or more prior systemic therapies [1][2][3].
In the 411 pre-treated EGFR T790M mutation-positive patients, the total overall response rate (ORR) was 66 % [95 % CI: 61, 71] — 62 % [95 % CI: 55, 68] in AURAex and 70 % [95 % CI: 63, 77] in AURA2. In patients with a confirmed response the median duration of response (DoR) was 12.5 months [95 % CI: 11.1, non estimable]. The medianprogression free survival (PFS) was 11.0 months [95 % CI (9.6, 12.4] [3].
A third study (AURA3) involved 419 patients and compared the efficacy of Tagrisso (osimertinib) in preventing the cancer from worsening, comparing it with a platinum-based chemotherapy (the standard treatment for NSCLC). In patients taking Tagrisso, the PFS was 10.1 months compared with 4.4 months in patients on chemotherapy. There were no significant differences in overall survival. The objective response rate was 71 % [95 % CI: 65, 76] in patients taking osimertinib and 31 % [95 % CI: 24, 40] in patients on standard chemotherapy. The duration of response was 9.7 months [95 % CI: 8.3, 11.6] on osimertinib vs 4.1 months [95 % CI: 3.0, 5.6] [3].

The most common side effects are diarrhoea, rash, dry skin, paronychia (nail infection), itching, stomatitis (inflammation of the lining of the mouth) and a decrease in the levels of white blood cells and platelets [4].
[1] Summary of Product Characteristics [FDA]: Tagrisso (osimertinib), AstraZeneca, Mar. 2017.
[2] Summary of Product Characteristics [EMA]: Tagrisso (osimertinib), AstraZeneca, May 2017.
[3] Summary of Product Characteristics [TGA]: Tagrisso (osimertinib), AstraZeneca, Dec. 2016.
[4] EMA. Human Medicines: Tagrisso (osimertinib), 17/02/2016 (last update: 02/03/2016), cited on 20/06/2017.
[5] FDA News Release: FDA approves new pill to treat certain patients with non-small cell lung cancer, 13/11/2015.
[6] FDA. Approved Drugs: Tagrisso (osimertinib), 30/03/2017, cited on 20/06/2017.

"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."

- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Share our website

Follow us

DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.